harmacologic coronary vasodilation in combination with single-photon emission computed tomography (SPECT) is a safe and effective method for the diagnosis of coronary artery disease. 1 Dipyridamole in conjunction with thallium imaging has been widely used as an alternative to exercise for patients unable to perform adequate exercise stress testing. 2,3 However, side-effects caused by dipyridamole administration are frequent and can be life-threatening, because of its prolonged pharmacologic effect (15-30 min when administered intravenously), and it is often necessary to eliminate side-effects with intravenous aminophylline infusion. [4][5][6][7] Dipyridamole is thought to be an indirect coronary vasodilator, and it acts by blocking the cellular uptake of the primary vasodilator, adenosine, and leads to subsequent increases in myocardial and arterial wall adenosine concentrations. Thallium-201 myocardial perfusion SPECT with adenosine has recently been introduced in Japan. Compared to dipyridamole, the side-effects of adenosine are also frequent but are mild, transient and well tolerated and do not require aminophylline administration because the plasma half-life of adenosine is exceedingly short (2-10 s), 8 and its effects disappear promptly upon discontinuation of adenosine infusion. 9 The short half-life of adenosine and the ability to regulate its infusion rate are useful properties, allowing for easy control of pharmacologic coronary vasodilation. However, adenosine is a very potent arteriolar vasodilator that can cause myocardial ischemia via a coronary steal phenomenon and can also decrease atrioventricular (AV) node conduction velocity. 10 In this study, we assessed the safety of and tolerance to thallium-201 myocardial perfusion SPECT with intravenous adenosine infusion in Japanese patients with suspected coronary artery disease.
Methods
PatientsDuring the period September 2005 to July 2006, 206 consecutive Japanese patients (106 men, 100 women; mean age, 68.9±10.5 years; range, 33-89 years) underwent thallium-201 myocardial perfusion SPECT with intravenous adenosine infusion for the evaluation of possible coronary artery disease. The research protocol was approved by the Institutional Review Board of the Sumitomo Besshi Hospital (Niihama, Japan), and patients were enrolled in the study after providing written informed consent. Exclusion criteria included hypotension (systolic blood pressure <90 mmHg), Circ J 2007; 71: 904 -910 (Received October 17, 2006; revised manuscript received February 8, 2007; accepted February 28, 2007
Safety of and Tolerance to Adenosine Infusion for Myocardial Perfusion Single-Photon Emission Computed Tomography in a Japanese PopulationKunihiko Hatanaka, MD* , *** , ****; Masayuki Doi, MD*; Satoshi Hirohata, MD*** , ****; Shigeshi Kamikawa, MD*; Yoko Kaji, MD*; Tsutomu Katoh, MD**; Shozo Kusachi, MD****; Yoshifumi Ninomiya, MD***; Tohru Ohe, MD**** Background Adenosine has been available for use in myocardial perfusion single-photon emission computed tomography (SPECT) in J...